The androgen receptor (AR) is expressed widely in breast cancer and has been proposed as a therapeutic target in patients who do not express the oestrogen receptor (ER). However, its role in women with ER-positive tumours is uncertain.
CDK4/6 inhibitors have significantly improved the survival of patients with HR-positive/HER2-negative breast cancer, becoming a first-line treatment option. However, the development of resistance to these inhibitors is inevitable. To address this challenge, novel strategies are required to overcome res...
(Herceptin) has been shown to dramatically reduce the risk of the cancer coming back. It‘s standard treatment to give this medication along withchemotherapyafter surgery to people with breast cancer that’s spread to other areas. It can also be used for early-stage breast cancer. But there ...
In women who had ER-positive disease (n = 10,645), tamoxifen significantly reduced the long-term risk for breast cancer recurrence and death. The relative risk (RR) for recurrence was nearly halved during tamoxifen treatment (0.53 during years 0 to 4). It was also significantly reduced, by...
While RUNX1 expression has not increased with E2 treatment (Supplementary Figure 1E). Therefore, we hypothesized that PAK4 entry into the nucleus influences RUNX1 subcellular localization. Our previous studies have shown that nuclear PAK4 promotes ERα positive breast cancer bone metastasis [10]. ...
Partridge continues. This often includes managing sexual health, psychological stress, and the long-term effects of therapies. Therefore, the care of young breast cancer patients should be holistic and proactive, addressing both immediate treatment concerns and future quality of life, ...
This invention relates to the treatment of androgen receptor-positive breast cancer in a subject, for example a female subject. Accordingly, this invention provides methods of: a) treating a subject suffering from breast cancer; b) treating a subject suffering from metastatic breast cancer; c) ...
also found CTx-648 treatment led to anti-tumor activity in tumors resistant to hormone therapy, a common line of treatment for ER-positive breast cancer patients. As such, the discovery of CTx-648 presents an exciting new opportunity to target KAT6A in patients with ER-positive breast cancer....
If given, such treatment should be continued for a minimum of 4-8 months. Selected patients with special types of breast cancer (e.g. pure tubular, cribriform and mucinous tumors) have a limited expected benefit from preoperative therapy and might receive adjuvant endocrine therapy alone. ...
Estrogen receptor (ER)-positive breast cancer represents approximately 70% of all breast cancers and the selec- tive ER modulator (SERM), tamoxifen, remains the mainstay of treatment in pre-menopausal women [1]. Although several studies have established the role of tamoxifen in significantly reduc...